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Introduction
The results of surgical treatment for lung cancer have been improved by early detection 70 and meticulous surgical procedures. However, we still face recurrence in patients with Response rates for platinum doublet therapy in patients with advanced lung cancer are 30-33%. 7 Conversely, S-1 showed a 22% response rate for advanced NSCLC in a previous phase II trial, 8 raising the question of whether S-1 has sufficient power as adjuvant advanced NSCLC, uracil-tegafur, another oral fluoropyrimidine, could be administered long-term (2 years) and, thus, could allow administration of sufficient amounts to prevent recurrence or metastasis, because the drug has extremely low toxicity and is easily continued as an oral medication. 9 Although the exact mechanisms of action accounting for the efficacy of uracil-tegafur treatment in the postoperative adjuvant setting remain unclear, long-term 100 uracil-tegafur administration may inhibit the development of postoperative recurrence through antiangiogenic effects in addition to direct cytotoxic effects. 10 In terms of S-1-based adjuvant chemotherapy, in the field of gastric cancer, a feasibility study has already been performed and achieved a high completion rate of 60% and a favorable drug compliance rate of 70%. 11 Furthermore, a phase III randomized study comparing surgery alone to surgery plus 105 adjuvant chemotherapy using S-1 was ongoing in 2005. 12 Given this background, we presumed that if long-term administration could be achieved in the postoperative adjuvant setting, similar factors would be applicable even for stage II to IIIA disease because of the higher response rate compared to uracil-tegafur.
Based on similar notions, a feasibility study for adjuvant chemotherapy was reported by 110 Yano et al. in 2010. 13 In that study, 56.7% of patients finished the regimen. Postoperative administration of S-1 for 6 months was thus considered feasible as adjuvant chemotherapy for NSCLC. However, the administration period of 6 months is half the reported duration of the adjuvant chemotherapy with S-1 12 and the completion rate is unsatisfactorily low despite the mildness of adverse reactions. Moreover, survival data from the study have yet to be 115 reported.
Tsuchiya et al., Page 8 To confirm the feasibility of 1-year administration of S-1 and analyse the effect of the intervention on prognoses, a multi-center phase II clinical trial was conducted in seven facilities. ; total bilirubin, ≤1.5 mg/dl; aspartate aminotransferase and alanine aminotransferase, less than twice the upper limits of normal at each institution; blood urea nitrogen, ≤25 mg/dl; creatinine, less than the upper limit of 150 normal at each institution; and creatinine clearance (Ccr) as estimated by the Cockcroft-Gault formula, ≥50 ml/min. When treatment was restarted within 14 days, the restart was judged to represent the same course after temporary discontinuation of drug administration. When treatment could not be restarted within 14 days, the course was skipped and restarted as the next course. Treatment was discontinued when the patient showed disease recurrence or 155 adverse reactions that were uncontrollable by dose modification and temporary discontinuation of drug administration. If a rest period >4 weeks was required, the patient was withdrawn from the study. National Cancer Institute Common Toxicity Criteria (NCI-CTC, 1998) were adopted for the evaluation of chemotherapy toxicity.
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Patients and Methods
Patient Eligibility
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Study Design and Statistical Analysis
This trial was non-blinded and open-label. The primary endpoint was the completion rate of the scheduled adjuvant chemotherapy. Secondary endpoints were the incidence and grade of adverse reactions. The number of patients to be enrolled in this study was calculated as 55.
Assuming a completion rate of 70%, with a planned eligible sample size of 50 patients, the 165 95% confidence interval (CI) for the completion rate was estimated to range from 55% to Tsuchiya et al., Page 10 82%. This completion rate of 70% means that 70% of patients would complete 48 weeks of planned chemotherapy.
The Kaplan-Meier method was used to estimate the time-to-event functions of relapse-free survival and overall survival. Relapse-free survival has been defined as the time 170 from the date of the start of treatment to the date of disease progression or death (whichever occurs first) or the date of last contact. Overall survival has been defined as the time from the date of the start of treatment to the date of death or last contact. The log-rank test was used to test for possible differences between estimated time-to-event curves.
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Ethics
This study was approved by the institutional review board at each site. Patients selected whether they would participate in the trial or not after detailed explanation and written informed consent was obtained from all patients prior to enrolment. In terms of one institution (Nagasaki University Hospital), 52 patients were referred to the trial. Among the 180 referred patients, 15 patients participated in the trial, 14 patients preferred to received uracil-tegafur (p-stage IB), and 23 patients preferred to received standard chemotherapy.
Results
Patient Characteristics
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A total of 51 patients were initially enrolled in the present study. One patients were ineligible, who rescinded consent to enter the trial before administration of S-1. Table 1 shows the characteristics of the 50 eligible patients. The median age of patients was 71.0 years (range, 32-80 years). Lobectomy was performed in all patients.
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Drug Compliance
Tsuchiya et al., Page 11 A total of 14 patients relapsed, and the relapse-free survival rate at 36 months was 69.4% (95%CI, 55.2-80.6) (Figure 1 ). Among the patients who experienced relapse, 6 patients experienced intrathoracic relapse, including five with regional lymphatic metastasis and one 230 with dissemination, and 8 patients showed distant relapse alone.
Adverse Reactions and Dose Reduction
Discussion
The present study was undertaken to confirm the feasibility of 1-year oral adjuvant chemotherapy with S-1 after standard resection for NSCLC. The completion rate for the 235 planned eight courses of S-1 administration was 72.0%, which compares favourably to the chemotherapy compliance seen on trials of cisplatin-based adjuvant therapies that have ranged from 45% to 76% of the intended dose. possibility of outpatient treatment with S-1 is convenient for both doctors and patients.
In the present study, the total percentage administration days and percentage administration dose were 77.3% and 71.1%. Whether a dose reduction of 70% allows sufficient power to prevent recurrence of lung cancer remains unclear. In analysis of a phase III study of postoperative gastric cancer, 12 when protocol completion cases were divided into 255 two groups according to compliance with S-1 administration, the 5-year survival curves for patients with ≥90% compliance and patients with 70% to <90% compliance overlapped (in-house experimental data; Taiho Pharmaceutical). We therefore believe a dose reduction of 70% provides sufficient adjuvant chemotherapy for lung cancer with S-1, as in gastric cancer.
Further studies and long-term observations are necessary to clarify the remaining issues.
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The regimen in the present study was based on the seminal phase III randomized study in postoperative gastric cancer. 12 Among the 517 patients in the safety population who received S-1, treatment was continued for 12 months in 340 patients (65.8%). In the present study, completion rates were 8% or more higher than those from the study in gastric cancer. In addition, our results showed incidences of hematological and non-hematological adverse reactions were both lower than in the gastric cancer study. As patients in the gastric cancer study displayed rather advanced disease and received D2 or more aggressive gastrectomy with frequent combined organ resections, patients who undergo standard resection for lung cancer might show better general and intestinal conditions for oral chemotherapy.
In a recent feasibility study of adjuvant chemotherapy with S-1 for NSCLC, 13 the 270 administration period of 6 months and the cycle of 2-week administration and 1-week withdrawal differed from the protocol applied in our study. That study demonstrated no hematological or non-hematological grade 4 adverse reactions throughout the eight courses, very similar to our study. Conversely, completion rate of the planned eight courses of S-1 administration was 56.7%. The reason for the relatively low completion rate was attributed to 275 the high age of patients and the high incidence of patients declining to continue treatment. 13 In the present study, dose reductions were performed without hesitation. When adverse reactions were encountered, dose reduction obviously improved the completion rate to 79.2%, compared to 36.4% without dose reduction. As a result, we achieved a high completion rate of 72.0%. The duration of S-1 administration is another area of discrepancy. Administration 280 of 5-FU is known to be more effective in producing direct cytotoxic effects against human tumor cells using lower doses for longer time periods than using higher doses for shorter times. 19 Our opinion is that at least a year of S-1 is warranted, unless clinical evidence to the contrary is identified.
The overall survival rate among patients with stage IB resected NSCLC was similar to One limitation of the present study was the difficulty in confirming true drug compliance.
We checked drug compliance from the treatment diary every 6 weeks when the patient visited 295 the hospital, but had no way of ensuring that the patient had made true declarations regarding drug intake. Although most seminal studies have not mentioned this point and one study applied a similar method, 1 investigators must keep in mind that all such oral administration studies conducted on an outpatient basis carry this problem in confirming true drug compliance.
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Although S-1 is not well known in Western countries, various clinical trials of S-1-based chemotherapy have been performed or are ongoing for advanced NSCLC, particularly in Japan. 20 Among chemotherapy-naïve patients with advanced NSCLC, a phase III trial by the West Japan Oncology Group showed oral S-1 plus carboplatin was non-inferior in terms of overall survival when compared to paclitaxel plus carboplatin. 21 Comparisons of 
Months
Survival rate
